Delving into the Latest Updates on Hangzhou Converd Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Infectious Diseases

Skin and Musculoskeletal Diseases

Oncolytic virus

Small molecule drug

Synthetic peptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Infectious Diseases	4
Nervous System Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Oncolytic virus	4
Small molecule drug	1
Synthetic peptide	1
Gene therapy	1
Bispecific T-cell Engager (BiTE)	1

Top 5 Target	Count

SRC(Tyrosine-protein kinase SRC)	1
CD3(T cell surface glycoprotein CD3)	1
IL-21R(Interleukin 21 Receptor)	1

Primary purpose: To evaluate the preliminary effectiveness of hV01 single intratumoral injection per cycle in the treatment of advanced sarcoma and cervical cancer. Secondary purpose: To further evaluate the safety of hV01 single intratumoral injection per cycle. Exploratory purpose: To explore the correlation between changes in peripheral blood immune-related indicators and efficacy.

Start Date09 Apr 2025

Sponsor / Collaborator

Hangzhou Converd Co., Ltd.

NCT05914376

/ RecruitingPhase 1

A Phase I Dose Escalation Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Biological Properties of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Patients With Advanced Malignant Solid Tumors

The goal of this clinical trial is to evaluate the safety, tolerance, pharmacokinetics, and biological properties of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced solid tumors.

Start Date05 Jul 2023

Sponsor / Collaborator

Hangzhou Converd Co., Ltd.

100 Clinical Results associated with Hangzhou Converd Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Hangzhou Converd Co., Ltd.

Login to view more data

100 Deals associated with Hangzhou Converd Co., Ltd.

Login to view more data

100 Translational Medicine associated with Hangzhou Converd Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 12 Jul 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

1

IND Application

Phase 1

1

Phase 2

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant human IL-21-expressing Oncolytic Vaccinia Virus (Hangzhou Converd)	Advanced Malignant Solid Neoplasm More	Phase 1
KX2-361 ( SRC )	Advanced Malignant Solid Neoplasm More	Phase 1
CVD-1301.H03	Herpes Simplex More	Clinical
CVD-1301.V01 ( IL-21R )	Poxviridae Infections More	IND Application
V 01 (HangZhou ConVerd)	Melanoma More	Preclinical